Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Core Insights - Arvinas, Inc. announced preclinical data for ARV-393 in combination with glofitamab, showing significant tumor growth inhibition in a model of diffuse large B-cell lymphoma (DLBCL) [1][3] - The company plans to initiate a Phase 1 clinical trial for this combination approach in 2026, aiming to provide a chemotherapy-free treatment option for patients with DLBCL [2][3] Group 1: Preclinical Data and Mechanism - The combination of ARV-393 (3 mg/kg) and glofitamab (0.15 mg/kg) achieved 81% tumor growth inhibition (TGI) with concomitant dosing and 91% TGI with sequential dosing, compared to 38% for ARV-393 alone and 36% for glofitamab alone [5] - At a higher dose of ARV-393 (6 mg/kg), the combination showed increased tumor regressions, with 10 out of 10 mice responding to concomitant dosing [5] - RNA sequencing indicated that ARV-393 upregulated CD20 expression and genes promoting interferon signaling, while downregulating proliferation-associated gene sets, contributing to the observed antitumor activity [5] Group 2: Clinical Development Plans - Arvinas is currently evaluating ARV-393 in a Phase 1 clinical trial for relapsed/refractory non-Hodgkin lymphoma and plans to share clinical data from this trial at a medical congress in 2026 [3] - The addition of a glofitamab combination cohort in the ongoing Phase 1 clinical trial of ARV-393 is planned for 2026 [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform, targeting various diseases including B-cell lymphomas [4][6] - The company is also advancing other investigational drugs targeting neurodegenerative disorders and mutated cancers [6]